SEC Form 4/A · accession 0001209191-18-032966
ImmunityBio, Inc. · IBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Steve Gorlin
Director
Period of report
May 21, 2018
Accepted (ET)
May 24, 2018 · 4:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326110
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | May 21, 2018 | S | 5,557 | $3.998 | D | 418,449 | I | By spouse |
| Common StockF2,F3 | May 22, 2018 | S | 8,546 | $3.9119 | D | 409,903 | I | By spouse |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the weighted average share price of an aggregate total of 5,557 shares sold in the price range of $3.97 to $4.01 by the reporting person's spouse. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F2This amendment is being filed to correct the weighted average share price for shares sold May 21, 2018 and May 22, 2018 as reported in the Form 4 filed on May 23, 2018.
- F3Represents the weighted average share price of an aggregate total of 8,546 shares sold in the price range of $3.91 to $3.925 by the reporting person's spouse. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.